| Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Financial Royalty Assets | 1,960 | 2,065 | 2,125 | 2,198 | 2,149 |
|---|
| Royalty Income, Other | 19 | 53 | 75 | 156 | 114 |
|---|
| Revenues | 2,122 | 2,289 | 2,237 | 2,355 | 2,264 |
|---|
| Provision for Other Credit Losses | - | - | 904 | 561 | 732 |
|---|
| Research and Development Expense | 26 | 200 | 177 | 52 | 2 |
|---|
| Amortization of intangible assets | 23 | 23 | 6 | - | - |
|---|
| General and Administrative Expense | 182 | 183 | 227 | 250 | 237 |
|---|
| Asset Impairment Charges | - | - | 616 | - | - |
|---|
| Total operating expense, net | 527 | 859 | 1,930 | 862 | 971 |
|---|
| Operating income | 1,595 | 1,431 | 307 | 1,492 | 1,292 |
|---|
| Equity in (earnings)/losses of equity method investees | 44 | -19 | -9 | 29 | 30 |
|---|
| Interest expense | - | - | - | - | 226 |
|---|
| Losses/(gains) on derivative financial instruments | -42 | -22 | 97 | -2 | -6 |
|---|
| (Gains)/losses on equity securities | 247 | -48 | -33 | 87 | 40 |
|---|
| (Gains)/losses on available for sale debt securities | - | 18 | -7 | 231 | 155 |
|---|
| Interest income | - | - | - | - | 47 |
|---|
| Other non-operating expenses, net | -33 | -6 | -15 | -22 | -2 |
|---|
| Total other (income)/expense, net | 107 | -190 | -77 | 208 | 38 |
|---|
| Consolidated net income before tax | 1,702 | 1,241 | 230 | 1,700 | 1,331 |
|---|
| Consolidated net income | 1,702 | 1,241 | 230 | 1,700 | 1,331 |
|---|
| Net income attributable to non-controlling interests | 727 | 621 | 187 | 565 | 472 |
|---|
| Net income attributable to Royalty Pharma plc | 1,702 | 1,241 | 230 | 1,700 | 1,331 |
|---|
| Earnings Per Share, Basic | 1.32 | 1.49 | 0.1 | 2.54 | 1.92 |
|---|
| Earnings Per Share, Diluted | 1.32 | 1.49 | 0.1 | 2.53 | 1.91 |
|---|